The lessons learned from randomized clinical trials of GERD

Digestive and Liver Disease

Volumn 39, Issue 11, 2007, Pages 993-1000

  Pace, F ^a   Sonnenberg, A ^b   Bianchi Porro, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

GERD; NERD; Placebo; PPI; RCT; Reflux oesophagitis

Indexed keywords

ANTACID AGENT; CIMETIDINE; CISAPRIDE; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; METOCLOPRAMIDE; NIZATIDINE; OMEPRAZOLE; PIRENZEPINE; PLACEBO; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; STOMACH SECRETION INHIBITOR; SUCRALFATE;

ANTIREFLUX OPERATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST CONTROL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEARTBURN; HUMAN; LOW DRUG DOSE; META ANALYSIS; OUTCOMES RESEARCH; PATIENT SATISFACTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; SHORT SURVEY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE ESOPHAGITIS;

GASTROESOPHAGEAL REFLUX; HUMANS; PLACEBO EFFECT; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVIEW LITERATURE AS TOPIC; TREATMENT OUTCOME;

EID: 35548984372     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2007.09.008     Document Type: Short Survey

References (37)

1. Pace F., and Bianchi Porro G. Clinical spectrum, natural history and epidemiology of GERD. In: Granderath F.A., Kamolz T., and Pointner R. (Eds). Gastroesophageal reflux disease. Principles of disease, diagnosis and treatment (2005), Springer, New York
2. Dent J. Microscopic esophageal mucosal injury in nonerosive reflux disease. Clin Gastroenterol Hepatol 5 (2007) 4-16
3. Stanghellini V., Armstrong D., Monnikes H., and Bardhan K.D. Systematic review: do we need a new gastro-oesophageal reflux disease questionnaire?. Aliment Pharmacol Ther 19 (2004) 463-469
4. Behar J., Brand D.L., Brown F.C., Castell D.O., Cohen S., Crossley R.J., et al. Cimetidine in the treatment of symptomatic gastroesophageal reflux. Gastroenterology 74 (1978) 441-448
5. Wesdorp E., Bartlesman J., Pape K., Dekker W., and Tytgat G.N. Oral cimetidine in reflux esophagitis: a double blind controlled trial. Gastroenterology 74 (1978) 821-824
6. Wesdorp E., Dekker W., and Kllinkenberg-Knol E.C. Treatment of reflux oesophagitis with ranitidine. Gut 24 (1983) 921-924
7. Klinkenberg-Knol E., Festen H., Jansen J., Meuwissen S., and Lamers C. Double blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet i (1987) 349-350
8. Bardhan K.D., Achim A., Riddermann T., and Pfanenberger B. A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving 'complete remission' in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 25 (2007) 1461-1469
9. Zacny J., Zamakhshary M., Sketris I., and Van Zanten V. Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 21 (2005) 1299-1312
10. Lind T., Havelund T., Lundell L., Glise H., Lauritsen K., Pedersen S.A., et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis-a placebo-controlled randomized trial. Aliment Pharmacol Ther 13 (1999) 907-914
11. Talley N.J., Lauritsen K., Tunturi-Hihnala H., Lind T., Moum B., Bang C., et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 15 (2001) 347-354
12. Talley N.J., Venables T.L., Green J.R., Armstrong D., O'Kane K.P., Giaffer M., et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 14 (2002) 857-863
13. Junghard O., Carlsson R., and Lind T. Sufficient control of heartburn in endoscopy-negative gastro-oesophageal reflux disease trials. Scand J Gastroenterol 12 (2003) 1197-1199
14. Van Rensburg C., Bardhan K.D., Tulassay Z., Kovacs T., Dorr M.B., Kliebsch U., et al. Pantoprazole 40 mg is comparable to esomeprazole 40 mg for first and sustained symptoms relief in patients with erosive gastroesophageal reflux disease (GERD). Gastroenterology 128 Suppl. 2 (2005) A-530
15. Gibson PG, Henry RL, Coughlan JL. Gastro-oesophageal reflux treatment for asthma in adults and children. The Cochrane Database of Systematic Reviews 2003, Issue 1. Art. No.: CD001496. doi:10.1002/14651858.CD001496.
16. Sonnenberg A., Lepsien G., Mueller-Lissner S.A., Koelz H.R., Siewert R., and Blum A.L. When is esophagitis healed? Esophageal endoscopy, histology and function before and after cimetidine treatment. Dig Dis Sci 27 (1982) 297-302
17. Khan M, Santana J, Donellan C, Preston C, Moayyedi P. Pharmacological therapies in the short term treatment of oesophagitis. The Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.: CD003244. doi:10.1002/14651858.CD003244.pub2.
18. Carlsson R., Dent J., Watts R., Riley S., Sheikh R., Hatlebakk J., et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 10 (1998) 119-124
19. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD003245. doi:10.1002/14651858.CD003245.pub2.
20. Caos A., Breiter J., Perdomo C., and Barth J. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. Aliment Pharmacol Ther 22 (2005) 192-202
21. Lundell L., Miettinen P., Myrvold H.E., Hatlebakk J.G., Wallin L., Malm A., et al. Seven-year follow-up of a randomized clinical trial comparing proton-pump inhibition with surgical therapy for reflux oesophagitis. Br J Surg 94 (2007) 198-203
22. Timmer R., Breumelhof R., Nadorp J.H., and Smout A.J. Oesophagits motility and gastro-oesophageal reflux before and after healing of reflux oesophagitis. A study using 24 h ambulatory and pressure monitoring. Gut 35 (1994) 1519-1522
23. DeVault K.R., and Castell D.O. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100 (2005) 190-200
24. Gralnek I.M., Dulai G.S., Fennerty B.M., and Spiegel B. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol 4 (2006) 1452-1458
25. Sonnenberg A. Review article: trials on reflux disease-the role of acid secretion and inhibition. Aliment Pharmacol Ther 20 Suppl. 5 (2004) 2-8
26. Pace F., Maconi G., Molteni P., Minguzzi M., and Bianchi Porro G. Meta-analysis of the effect of placebo on the outcome of medically treated reflux esophagitis. Scand J Gastroenterol 30 (1995) 101-105
27. Dean B.B., Gano A.D., Knight K., Ofman J.J., and Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2 (2004) 656-664
28. Spechler S.J., Lee E., Ahnen D., Goyal R.K., Hirano I., et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease. J Am Med Assoc 285 (2001) 2331-2338
29. Pace F., Molteni P., and Wiklund I. Outcome research in gastroenterology: the case of gastroesophageal reflux disease. Drug Dev Res 67 (2006) 251-259
30. Epstein R.S., and Sherwood L.M. From outcomes research to disease management. A guide for the perplexed. Ann Intern Med 124 (1996) 832-837
31. The Outcomes of Cancer Outcomes Research. Focusing on the National Cancer Institute's Quality of Care Initiative. Med Care 2002;40:3-10.
32. Epstein A.M. The outcomes movement-will it get us where we want to go?. N Engl J Med (1990) 266-270
33. Wiklund I. Quality of life in patients with gastroesophageal reflux disease. Am J Gastroenterol 96 (2001) S46-S53
34. Prasad M., Rentz A.M., and Revicki D.A. The impact of treatment for gastro-oesophageal reflux disease on health-related quality of life. A literature review. Pharmacoeconomics 21 (2003) 769-790
35. Wiklund I., Hansen A., Bergheim R., and Moum B. Esomeprazole is superior to ranitidine 150 mg bid in maintaining quality of life (QoL) in patients with symptomatic GERD. Scand J Gastroenterol 38 (2003) 22
36. Dent J., El-Serag H.B., Wallander M.A., and Johansson S. Epidemiology of gastro-oesophageal reflux: a systematic review. Gut 54 (2005) 710-717
37. El-Serag H.B. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol 5 (2007) 17-26